HOOPER, LUNDY & BOOKMAN, P.C. lobbying for BRAINFUTURES

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 19, 2026

Income

$40,000.00

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Lobbyists on this filing 1

LISA LAYMAN New on this filing

Previously held: SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 2623
Innovative Therapies Centers of Excellence Act of 2025
S 4220
Veterans Health Administration Novel Therapeutics Preparedness Act

Lobbying activity 4

Health Issues

Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.

Medical/Disease Research/Clinical Labs

Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.

Budget/Appropriations

FY2027 budget related to psychedelic therapies for treatment of mental health and substance use disorders.

Veterans

H.R.2623 - Innovative Therapies Centers of Excellence Act of 2025, S. 4220 - Veterans Health Administration Novel Therapeutics Preparedness Act.